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Occurrence of deoxynivalenol in an elderly cohort in the UK: a 29 
biomonitoring approach  30 
Deoxynivalenol (DON) is a Fusarium toxin, to which humans are frequently exposed via diet. 31 
Despite elderly are speculated to be sensitive to the toxic effects of DON as a result of age-32 
related conditions, disease and altered DON metabolism, there is lack of available data on DON 33 
biomarkers in this age group. This study characterised urinary DON concentrations and its 34 
metabolites in elderly aged ≥ 65years (n=20) residing in Hull, UK. Morning urinary specimens 35 
were collected over two consecutive days together with food records to assess dietary intake 36 
over a 24h-period prior to each urinary collection. Free DON (un-metabolised), total DON 37 
(sum of free DON and DON-glucuronides or DON-GlcA) and de-epoxy deoxynivalenol 38 
(DOM-1) were analysed using a validated LC-MS/MS methodology. Total DON was detected 39 
in 90% of elderly men and women on both days. Mean total DON concentrations on day 1 were 40 
not different from those on day 2 (elderly men, day 1: 22.2 ±26.3 ng/mg creat, day 2: 28.0±34.4 41 
ng/mg creat, p=0.95; elderly women, day 1: 22.4 ±14.6 ng/mg creat, day 2: 29.1±22.8 ng/mg 42 
creat, p= 0.58). Free DON and DON-GlcA were detected in 60-70% and 90% of total urine 43 
samples respectively. DOM-1 was absent from all samples. Estimated dietary intake of DON 44 
suggested that 10% elderly exceeded the maximum provisional tolerable daily intake for DON. 45 
In this single-site, UK-based cohort, elderly were frequently exposed to DON, although mean 46 
total DON concentrations were reported at moderate levels. Future larger studies are required 47 
to investigate DON exposure in elderly from different regions of the UK, but also from different 48 
counties worldwide. 49 
Keywords: mycotoxins; deoxynivalenol; Fusarium graminearum; biomonitoring; elderly 50 
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Introduction 53 
The trichothecene deoxynivalenol (DON), also known as vomitoxin, is a secondary 54 
metabolite of Fusarium graminearum and Fusarium culmorum, to which humans and 55 
animals are predominantly exposed via food and feed (Pestka and Smolinski 2005; Pestka 56 
2010; European Food Safety Authority 2013). As a result of its solubility in water and 57 
stability during cooking (temperatures 120 °C), storage conditions and milling processes, 58 
DON contaminates cereal grains and remains to a large extent unaffected during manufacture 59 
(Bretz et al. 2006; Scudamore et al. 2009). Thus, it can be also found in cereal-based 60 
derivative products including breakfast cereals, bread, confectionary, beer, infant formulas, 61 
and baby foods (Scudamore et al. 2009; European Food Safety Authority 2013). Several 62 
animal studies have shown that acute DON exposure cause anorexia, vomiting, abdominal 63 
pain and diarrhoea, while lifetime exposure to DON has also been associated with 64 
reproductive impairments, neuro- and immuno-toxicity (Pestka 2010). Acutely, humans 65 
appear to be affected in a similar way as animals following high DON intake, confirming that 66 
the gastrointestinal track is a main target for DON toxicity (Pestka and Smolinski 2005; 67 
Pestka 2010; European Food Safety Authority 2013). In contrast, the chronic effects of DON 68 
exposure in humans are uncertain, and their study is hampered by challenges in assessing risk 69 
exposure, together with difficulties in differentially identifying symptoms of DON toxicity 70 
from those due to other illnesses (Etzel 2006; Marin et al. 2013).  71 
Advances in biomonitoring with the development of highly sensitive analytical 72 
procedures have allowed the assessment of DON and its main metabolites in urine (Turner 73 
et al. 2008). DON can be excreted in urine in its un-metabolised form (free DON) or after 74 
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being converted to its metabolites (Turner et al. 2008). In brief, DON can be conjugated to 75 
glucoronides (DON-GlcA) in the liver and possibly in the intestine and kidneys, with 76 
deoxynivalenol-3-glucuronide (DON-3-GlcA) and deoxynivalenol-15-glucuronide (DON-77 
15-GlcA) being two of the main DON metabolites currently identified (Pestka and Smolinski 78 
2005; Pestka 2010; European Food Safety Authority 2013). Deepoxy-DON (DOM-1) has 79 
been characterised as another major metabolite of DON produced by gut microbiota with 80 
deepoxidase activity in mammals (Pestka and Smolinski 2005; Pestka 2010; European Food 81 
Safety Authority 2013). DOM-1 has been inconsistently detected in human biological 82 
samples (Turner et al. 2010a; 2010b; Follmann et al. 2016; Wells et al. 2017), and remains 83 
uncertain, if human microbiota naturally possesses de-epoxidase activity, or whether rumen 84 
microbiota, which effectively converts DON to DOM-1, is transferred to humans during their 85 
contact with animals (Turner et al. 2010a; Wu et al. 2010). Biomonitoring studies in human 86 
adults have shown great variability in exposure to DON, as evaluated by the frequency of 87 
detection and biomarker concentrations in urine specimens (Turner, et al. 2010a; 2010b; 88 
Turner et al. 2011; Warth et al. 2012; Shephard et al. 2013; Heyndrickx et al. 2015; Gerding 89 
et al. 2014; Rodriguez-Carrasco et al. 2014; Solfrizzo et al. 2014; Gerding et al. 2015; Wallin 90 
et al. 2015; Follmann et al. 2016; Wells et al. 2017). These differences can be largely 91 
explained by geographical differences and eating patterns, whilst differences in population 92 
characteristics (e.g., age, physiological/disease status) may also contribute to these results.  93 
Elderly may be an adult subpopulation at increased risk of experiencing toxicological 94 
effects when they are exposed to fungal toxins, including DON. DON toxic effects including 95 
anorexia, nausea, diarrhoea and stomach pain are similar to and may even exacerbate 96 
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symptoms associated with age-related conditions and diseases common amongst elderly 97 
(Talley et al. 1992; Martone et al. 2013). Although data from human studies are currently 98 
lacking, this notion is supported by findings in animal models suggesting increased 99 
susceptibility of aged animals to the negative side effects (i.e., anorexia) of DON exposure 100 
compared to young adult animals (Clark et al. 2015). Ageing is accompanied by several 101 
physiological and metabolic changes including a reduction in renal and hepatic clearance 102 
(Mangoni and Jackson 2004), which in turn, may modify the way DON is absorbed, 103 
distributed, metabolised and excreted. Alterations in intestinal microbiota composition with 104 
increasing age have also been reported in humans (Claesson et al. 2011), albeit it remains 105 
unknown if such changes would affect the detoxification of DON. Conversely, a significant 106 
reduction in food intake has been reported with advancing age (Drewnowski 2000; 107 
Wakimoto and Block 2001), which suggests a lower DON intake in elderly through this main 108 
route of exposure. To our knowledge, elderly have not been previously considered as a 109 
separate population group with distinct characteristics compared to those of their younger 110 
counterparts within DON-related biomonitoring research.  111 
 This study aimed to characterise DON concentrations and its metabolites in urine of 112 
elderly individuals aged ≥65 years residing in Hull, UK. To allow comparison with younger 113 
adults, a dataset of UK adults aged 18-64 years residing in the same area, previously 114 
published as part of our ongoing work in this area of research, was used (Wells et al. 2017).  115 
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Materials and Methods  116 
Participants selection and recruitment  117 
Elderly aged ≥65 years (n=20) and adults aged 18-64 years living in the Hull and East 118 
Yorkshire were recruited via word of mouth, by an announcement in the local newspapers 119 
and an email distributed by the University of Hull and Hull and East Yorkshire Hospitals 120 
NHS.  121 
Inclusion criteria were being in general good health, not taking any current 122 
medication initiated within the last 3 months or were on stable medication (over a duration 123 
>3 months). Exclusion criteria were inability to provide informed consent, acute or chronic 124 
illness (chronic renal, hepatic or cardiac problems, cancer), chronic gastrointestinal 125 
conditions (e.g., coeliac disease), gluten sensitivity, eating disorders, depression, psychosis 126 
or hospitalisation within the last three months prior to enrolment in the trial or participation 127 
in a weight loss programme. Individuals on stable medication, which may influence appetite 128 
such as oral steroids, were not included in the study. 129 
Ethical approval was granted by the National Health Service (NHS), National 130 
Research Ethics Service (NRES) Committee Yorkshire & the Humber-Leeds West (IRAS 131 
project code: 147707).  132 
Study design  133 
This dataset analysed in the present study consists part of a more comprehensive investigation 134 
entitled “Experimental study of deoxynivalenol biomarkers in urine” performed for the 135 
European Food Safety Authority GP/EFSA/CONTAM/2013/04 (Brera et al. 2015), which 136 
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investigated the presence of DON and DON metabolites in urine samples collected from 137 
children (aged 3-9 years), adolescents (aged 10-17 years), adults (aged 18-64 years), pregnant 138 
women and elderly (aged ≥65 yeas) (total n=635) in the UK, Italy and Norway. 139 
A validated, semi-quantitative food frequency questionnaire (FFQ) (previously used 140 
in (Brera et al. 2015; Wells et al. 2016; Wells et al. 2017), was designed to assess food 141 
consumption of cereal grains and cereal-based products that commonly contribute to DON 142 
dietary exposure over a month recall period, while a food record was used to collect detailed 143 
information about food items consumed 24hours preceding the collection of each urine 144 
sample. Age, height, weight and physical activity were self-reported as part of the FFQ. 145 
Participants were supplied with four urine collection containers of 50 mL each and written 146 
guidance for collecting their first morning urine samples at home, on two consecutive days. 147 
This timeframe was intended to cover potential between-day variability within participant 148 
and enhance the repeatability of our findings. Participants returned the urine samples at the 149 
Hull Royal Infirmary (Hull, UK) on the same day of collection. All samples were centrifuged 150 
at 2000 rpm for 10 minutes and stored at -80°C until further analysis. DON and its 151 
metabolites were tested using the validated HPLC-MS/MS methodology as previously 152 
described in (Turner et al. 2008).  153 
Laboratory analysis 154 
DON and its metabolites were analysed using 13C labelled DON standard (Sigma, Saint 155 
Louis, MI, USA; product number: 34128, 1.2 mL), DON (Sigma, Saint Louis, MI, USA; 156 
product number: D0156, 1 mg), β-glucuronidase (Type IX-A from E. coli; Sigma, Saint 157 
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Louis, MI, USA; product number: G7396 - 2MU), DOM-1 (Sigma, Saint Louis, MI, USA; 158 
product number: 34135, 2 mL), and DON test WBTM immunoaffinity columns (Vicam, 159 
Milford, MA, USA; product number: G1066). All analyses were conducted on a Waters 2795 160 
HPC Separation Module (Waters Corp., Milford, MA, USA) with a Quattro Micro Triple 161 
Quadrupole Mass Spectrometer (Micromass UK Ltd., Manchester, UK). 162 
Sample preparation 163 
Stored urine samples were centrifuged at 2000 rpm at -4 °C for 15 minutes. For each 164 
participant, two aliquots (1 mL) were prepared by mixing 13C-DON internal standard solution 165 
to a final concentration of 20 ng/mL. In the first aliquot, total DON was determined as the 166 
sum of DON-GlcAs and free DON. For measuring the combined DON-GlcAs (DON-3-GlcA 167 
and DON-15-GlcA) and free DON, each sample was set to pH 6.8 and treated with β-168 
glucuronidase solution (23,000 units, in KH2PO4 75 mM) in a shaking water bath at 37 °C 169 
for 18 hours. The samples were then centrifuged (2000 rpm; -4 °C; 15 min), and the 170 
supernatant was diluted to a final 4 mL with phosphate buffered saline (PBS, pH 7.4), before 171 
being passed through a wide bore DON immunoaffinity column. DON was removed from 172 
columns with methanol (4 mL) and extracts were dried under vacuum using a SavantTM 173 
SpeedVacTM (Thermo Fisher Scientific Inc., Waltham, MA, USA) or equivalent and 174 
dissolved in 10% ethanol (250 μL) for LC-MS analysis. DOM-1 was quantified on the same 175 
aliquot analysed for DON-GlcA. Free DON was assessed in the second aliquot using the 176 
same procedures, but no β-glucuronidase treatment was performed. 177 
 9 of 30 
HPLC-MS analysis: DON determination 178 
The separation of DON was performed by utilising reversed phase chromatography using a 179 
Luna C18 column (150 × 4.6 mm, 5-μm particle size) (Phenomonex, Macclesfield, UK) with 180 
a mobile phase sequence of 27 minutes 20% methanol, reconstructed to a wash of 75% 181 
methanol after 10 minutes followed by 20% methanol after 16 minutes (flow rate 1 mL/min; 182 
injection volume 25μL). One fifth of the eluent was placed into the desolvation chamber of 183 
the MS. Selective ion recording (SIR) was used to quantify DON with respect to 13C-DON 184 
internal standard. The following mass spectrometer conditions were kept stable: capillary 185 
voltage 3.5 kV, desolvation temperature: 300 °C, extraction cone voltage: 3.00 V, sampling 186 
cone voltage: 35.00 V, source temperature: 100 °C, cone gas flow: 50 L/h, collision energy: 187 
1.0 and desolvation gas flow 500 L/h. Two masses of DON ([DON-H]+, m/z 297.2 and 188 
[DON-Na]+, m/z 319.2) and 13C-DON ([13C-DON-H]+, m/z 312.2 and [13C-DON-Na]+, m/z 189 
334.2) were monitored for 0.25 seconds (each mass) and were then summed to form a total 190 
ion current peak for the internal standard and each analyte. The calibration curve (range 2-191 
250 ng/mL) was established by injecting DON and 13C-DON standard solutions (prepared in 192 
10% ethanol) DON-GlcA concentrations were estimated indirectly, by subtracting free DON 193 
from total DON values.  194 
LC-MS analysis: DOM-1 determination 195 
DOM-1 was separated by utilising the same chromatographic column used for DON 196 
separation combined with a mobile phase sequence of 35 minutes 20% methanol, changed to 197 
a wash of 75% methanol after 20 minutes and then to a phase of 20% methanol after 26 198 
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minutes (injection volume 25 L; flow rate 1 mL/min). Part of the eluent was driven into the 199 
MS desolvation chamber. Similar to DON analysis, DOM-1 was quantified by SIR with 200 
reference to the calibration curve (range of 2–200 ng/mL), which resulted from the injection 201 
of DOM-1 standard solutions (prepared in 10% ethanol). Each of two masses of DOM-1, 202 
[DOM-1-H]+, m/z 281.3 and [DOM-1-Na]+, m/z 303.3 were monitored (0.25 seconds) and  203 
summed to obtain a total ion current peak for DOM-1. 204 
Analysis of creatinine  205 
Adjustments of DON concentrations for creatinine were used to account for differences in 206 
dilution between individuals that may have resulted from the sole collection of a first morning 207 
urine samples. An in-house micro-titre plate assay was used to determine urinary creatinine. 208 
Samples were diluted in water (1:20) and 100 µL was added, in duplicate, to a 96-well plate. 209 
A duplicate standard curve of creatinine concentrations within the range 0-20 μg/mL was 210 
obtained for each plate. A further100 μL of alkaline picric acid solution was added to each 211 
well, incubated at 25 °C for 30 minutes and measured at 490 nm using a plate 212 
spectrophotometer. Urinary total DON concentrations are presented as unadjusted (ng/mL) 213 
and adjusted for creatinine (ng/mg creatinine).  214 
Estimated dietary exposure of DON based on urinary analysis 215 
The estimated dietary exposure of DON was calculated using formula 1 (Ezekiel et al. 2014; 216 
Heyndrickx et al. 2015):  217 
Estimated dietary exposure of DON (μg/kg b.w./day) = total DON x V
ER x b.w. ∗ 1000 (1) 218 
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Total DON = unadjusted total DON concentrations in urine  219 
ER = urinary excretion rate of DON is 72% (Turner et al. 2010b).  220 
V = daily urine output (mL/day) was estimated to be 1.5 L 221 
b.w. = self-reported body weight (kg)  222 
Based on the toxicological data in animals and humans, the Joint Food and Agriculture 223 
Organization of the United Nations (FAO)/World Health Organisation (WHO) Expert 224 
Committee on Food Additives (JECFA) have set a provisional maximum tolerable daily 225 
intake (PMTDI) at 1 μg/kg body weight (b.w.) day for DON and its main metabolites (Joint 226 
Expert Committee on Food and Additives, 2010). As such, we compared the estimated 227 
dietary exposure of DON with PMTDI at μg/kg b.w./day and characterised exposure as below 228 
or exceeding PMTDI.  229 
Dietary assessment and analysis 230 
In this report, the results of the food records covering the dietary intake over a 24-h period 231 
prior to each urinary samples collection are only reported. The food records included the 232 
following food categories that are commonly contaminated with DON: breakfast cereals and 233 
snacks, bread, products alternative to bread, flakes, cereals, other breads, biscuits, bakery 234 
goods, pizza, pasta, wheat germ, beer, pancakes and pita bread. These categories are in line 235 
with the validated FFQ designed to assess DON exposure though diet and used in previous 236 
DON-related research (Brera et al. 2015; Wells 2016; 2017). Each of the two food records 237 
included three main meals (breakfast, lunch, dinner) and snacks. For each of these eating 238 
occasions, examples of food items belonging to the aforementioned food categories were 239 
included. To enhance consistency and enable participants to record intake in an easy way, 240 
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each category was tabulated with tick boxes as to whether the portion consumed was small, 241 
medium or large. Photographic examples of portion sizes were also used to help participants 242 
to accurately quantify their dietary intake. Importantly, participants completed food records 243 
at the presence of research dietitians, who provided clarification and asked supplementary 244 
information. Portion sizes reported in the food records were converted into grams by research 245 
dietitians prior to data analysis.  246 
 Statistical Analysis  247 
All numerical data were checked for normality using the Shapiro-Wilk test. Urinary DON 248 
levels between day 1 and day 2 within adults and elderly were compared using a paired t-test 249 
and a Wilcoxon signed-rank test for normally and non-normally distributed respectively. 250 
Comparisons between groups were performed using an independent t-test or Mann-Whitney 251 
test for normally and non-normally distributed, respectively. Fisher's exact test was used for 252 
comparing categorical variables. The association between urinary DON levels and its 253 
metabolites and sex, weight, BMI and dietary intake of commonly foods contaminated with 254 
DON were assessed using the Spearman’s correlation coefficient (two-tailed). All analyses 255 
were carried out using IBM SPSS Statistics Version 24.0. Results were deemed significant 256 
at a p-value ≤0.05.  257 
Results 258 
Baseline characteristics 259 
A total of 50% of the 20 elderly (aged ≥65 years) and 52% of the 31 adults (aged 18-64 years) 260 
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were men. Baseline characteristics of elderly and adults by sex are shown in Table 1. Men 261 
were significantly taller (elderly, p=0.15; adults, p<0.001) and heavier (elderly, p=0.04; 262 
adults, p<0.001) than women in both the elderly and adult groups. There was a trend towards 263 
a higher BMI in elderly men than women (p=0.051) and BMI was not different between adult 264 
men than women (p=0.10). Elderly men were significantly shorter than adult men (p=0.03), 265 
but there were no further differences in weight (p=0.28) and BMI (p=0.63). Height (p=0.34), 266 
weight (p=0.22) or BMI (p=0.36) did not differ between adult and elderly women. In all 267 
groups, most of the participants reported moderate physical activity (elderly men, 80%; 268 
elderly women, 70%; adult men, 50%; adult women, 80%), and there were no significant 269 
differences for physical activity categories among groups (p-values from 0.14 to 0.49). 270 
Elderly women had significantly lower urinary creatinine levels (mg/dl) than elderly men 271 
(p=0.003) and adult women (p=0.004), which is in line with sex and age differences shown 272 
previously (Barr et al., 2005).  273 
Total DON Concentrations in Urine Samples  274 
Table 2 presents unadjusted and creatinine-adjusted DON concentrations in urine samples on 275 
day 1 and 2 in elderly (n = 20) and adults (n = 31). Total DON was detected in 90% of elderly 276 
men and women on both days and 100% of adult men and women on days 1 and 2. Mean 277 
total creatinine-adjusted DON concentrations (ng/mg creat) on day 1 were not different from 278 
total DON concentrations on day 2 in elderly (men, day 1: 22.2 ±26.3, day 2: 28.0±34.4, 279 
p=0.95; women, day 1: 22.4 ±14.6, day 2: 29.1±22.8, p= 0.58) or adults (men, day 1: 24.3 280 
±38.2, day 2: 21.3±19.1, p=0.41; women, day 1: 12.7 ±7.9, day 2: 18.2±18.0, p=0.82) (Table 281 
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2). Mean total creatinine-adjusted DON concentrations (ng/mg creat) for both days (pooled 282 
data for day 1 and day 2) were 25.1 for elderly men (n =10) and 22.8 for adult men (n = 16), 283 
with no differences found between the two groups (p=0.70). Although greater mean total 284 
DON concentrations (pooled data for day 1 and 2) were reported in elderly women 285 
(25.7±17.4 ng/mg creat) compared to those in adult women (15.5±11.2 ng/mg creat), these 286 
did not reach statistical significance (p=0.079).  287 
DON metabolite concentration in urine samples  288 
Free DON (>limit of quantification or LOQ 0.25 ng/mL) was detected in 60-70% of elderly 289 
men and women, and in all urine samples of adults. DON-GlcA (>LOQ 0.50 ng/mL) was 290 
present in elderly (90%) and adults (100%) samples. In contrast, DOM-1 was absent from all 291 
samples of both age groups. In elderly subjects, DON-GlcA made significant contribution 292 
ranging from 83 to 91% of the total DON and free DON represented 9-17% of total DON; 293 
with these contributions being very similar among elderly and adults (Table 2).  294 
Mean free DON concentrations (ng/mg creat) were 3.8 and 3.2 on day 1 and day 2 in 295 
urinary specimens of elderly men and 2.3 and 2.8 for days 1 and 2 in samples of elderly 296 
women (Table 2). In adult men, mean urinary levels of free DON were reported to be 4.2 and 297 
3.2 ng/mg creat on days 1 and 2, while the respective values in adult women were 1.9 and 298 
2.8 ng/mg creat (Table 2). There were no differences in mean free DON concentrations 299 
between day 1 and day 2 in elderly (men, p=0.50; women, p=0.58) or adults (men, p=0.50; 300 
women, p=0.45). Furthermore, mean free DON concentrations (pooled data for days 1 and 301 
2), were not significantly different between elderly and adult men (elderly men: 3.5±4.3 302 
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ng/mg creat vs. adult men: 3.7 ±4.8 ng /mg creat; p=0.52) or women (elderly women: 2.3±1.6 303 
ng/mg creat vs. adult women: 2.6±1.6 ng /mg creat; p=0.74).  304 
Amongst elderly individuals, mean DON-GlcA (ng/mg creat) concentrations were 305 
18.5 and 21.8 on days 1 and 2 in men and 20.1 and 26.3 for days 1 and 2 in women (Table 306 
2). Among adults, mean urinary levels of DON-GlcA (ng/mg creat) for days 1 and 2 were 307 
20.0 and 18.1 for men and 10.8 and 15.4 for women (Table 2). There were no differences 308 
between days 1 and 2 in any group (elderly men, p=0.95; elderly women, p=0.21; adult men, 309 
p=0.41; adult women, p=0.96). When DON-GlcA (ng/mg creat) data were pooled for both 310 
days, no differences were seen between elderly and adult men (elderly men: 20.1±15.1 ng/mg 311 
creat vs. adult men: 19.1±22.1 ng /mg creat; p=0.62) or elderly and adult women (elderly 312 
women: 23.2±16.4ng/mg creat vs. adult women: 13.1±9.7 ng /mg creat; p=0.067). 313 
Estimated dietary DON exposure using urinary total DON concentrations   314 
We carried out a risk assessment by comparing the estimated dietary intake of DON with the 315 
PMTDI of 1 μg/kg b.w./day. The mean estimated dietary intake of DON was 0.43 316 
μg/kg·b.w./day (minimum: 0, maximum: 2.33) for elderly and 0.37 μg/kg·b.w./day 317 
(minimum: 0.07, maximum: 1.33) for adults. In total, 10% of elderly and <3% of adults were 318 
estimated to exceed the PMTDI of 1 μg/kg b.w./day.  319 
Correlation between urinary DON, demographic and anthropometric 320 
characteristics 321 
In elderly, no correlations were found between urinary mean total DON (ng/mg creat) (pooled 322 
data for day 1 and day 2) and sex (r=-0.43; p=0.86), height (r= -0.128; p=0.59), weight (r=-323 
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0.294; p=0.21) or BMI (r=-0.259, p=0.27).  324 
Correlation between urinary total DON and Food Intake 325 
Table 3 presents main food categories commonly consumed by elderly and adults, which are 326 
often contaminated with DON. One adult participant had a total intake of all food categories 327 
equal to 0 on both experimental days, which is unlikely given the characteristics of our 328 
cohorts (healthy individuals, not under energy restriction). Therefore, this participant was 329 
excluded from this correlation analysis between urinary total DON and main food categories 330 
contributing to DON exposure. Analysis was performed in 20 elderly and the remaining 30 331 
adults with complete data. Elderly consumed significantly more flakes (p=0.016), biscuits 332 
(p=0.033) and baked good (p=0.044) compared to adults. There were no other differences for 333 
any other food category between the two age groups (p values from 0.066 to 0.57). Total 334 
intake of commonly contaminated foods with DON did not differ between the elderly 335 
compared to adults (p=0.28). In elderly, no significant correlations were found between 336 
urinary mean total DON (ng/mg creat) for both days and any food category that commonly 337 
contribute to dietary DON exposure (p values from 0.056-0.93). In a pooled analysis of 338 
elderly and adults, urinary mean total DON (ng/mg creat) for both days were positively 339 
correlated with flakes consumption (r=0.426, p=0.02), but not with any other food category 340 
or total intake of commonly contaminated foods with DON (p values from 0.13 to 0.95) 341 
(Table 3).  342 
 343 
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Discussion  344 
Elderly individuals may be particularly susceptible to DON exposure due to age-related 345 
alterations in absorption, distribution, metabolism and excretion of toxins, but also as a result 346 
of diseases, which may resemble or increase sensitivity to the toxic effects of DON on bodily 347 
systems (Mangoni and Jackson 2004; Clark et al. 2015). Our study provides data on the 348 
concentrations of DON and its metabolites in urine samples of elderly individuals. A frequent 349 
detection of total DON (90%) at a mean concentration of 25.4 ng/mg creat, suggests DON 350 
exposure, although at relatively moderate levels in this small cohort in elderly. Compared to 351 
adults aged 18-64 years residing in the same area, elderly appeared to have similar urinary 352 
levels of DON, indicating no significant differences in DON exposure with age.  353 
Comparative data in elderly are only available as part of our larger investigation, 354 
which in addition to the UK, included participants from Norway and Italy (Brera et al. 2015). 355 
Mean total DON concentrations in UK elderly (n=20, incidence=90%, mean levels=25.4 356 
ng/mg creat) were almost 3-fold to those detected in the elderly cohorts in Norway (n=20, 357 
incidence=100%, mean levels=8.9 ng/mg creat) and Italy (n=20, incidence=100%, mean 358 
levels=8.3 ng/mg creat) (Brera et al. 2015). Most available studies in adult populations have 359 
not included elderly individuals (aged ≥65 years), whereas those, that have included 360 
participants ≥65 years, have treated them as part of a mixed group of adults (≥18 years) 361 
(Turner et al. 2010a; 2010b; Turner et al. 2011; Warth et al. 2012; Gerding et al. 2014; 362 
Heyndrickx et al. 2015; Follmann et al. 2016). Similarly to our study in elderly and adults 363 
based in a single urban area in the UK, current findings from European counties suggest that 364 
adults are frequently exposed to DON, however, the magnitude of exposure is highly variable 365 
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(Germany: n=30, incidence=100%, mean levels=6.0 ng/mg creat (Föllmann et al. 2016); 366 
Belgium: n=239, incidence 100%, mean levels: 87.9 ng/mg creat (Heyndrickx et al. 2015); 367 
Spain: n = 22; incidence: 73%, mean levels = 14.8 ng/mg creat (Rodriguez-Carrasco et al. 368 
2014); Sweden: n=252, incidence: 63%, mean levels=7.0 ng/mg (Wallin et al. 2015); Italy: 369 
n=52, incidence: 96%, mean levels=11.9 ng/mL (Solfrizzo et al. 2014); and Austria: n=27, 370 
incidence=96%, mean levels =20.4 ng/mL (Warth et al. 2012). Similar findings have also 371 
been reported in non-European countries including China (Turner et al. 2011), South Africa 372 
(Shephard et al. 2013) and Haiti (Gerding et al. 2015). The variability in the results may 373 
reflect differences in exposure as a result of dietary patterns, climate conditions, cultivating 374 
and processing or may be due to differences in study design, characteristics of study 375 
populations or analytical procedures and lower limits of quantification used for urinary DON 376 
assessment.  377 
Understanding the metabolism of DON in elderly is important in characterizing the 378 
risk of this population to the toxic effects of DON exposure. Towards this end, free DON 379 
(unmetabolised form of DON) was found in 60-70% of the urine samples of the elderly 380 
individuals. DON-GlcA was detected in 90% of all urine specimens of elderly individuals. 381 
In the positive samples, free DON accounted for 9-17% of the total DON concentrations; 382 
whilst DON-GlcA made the greatest contributions to total DON concentrations ranging from 383 
83-91%. Our results suggest that conjugation to glucuronides is the main detoxification route 384 
for DON in elderly humans. Similarly to our elderly cohort, contributions of DON-GlcA over 385 
80% of total DON concentrations were evident in our adult cohort. Our findings in elderly 386 
and adults individuals are in line with those of previous studies in adult populations (Turner 387 
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et al. 2011; Warth et al. 2012; Heyndrickx et al. 2015; Gerding et al. 2014). Few studies have 388 
also given insight into the different conjugates (Warth et al. 2012). For example, in a study 389 
in Austrian adults, DON-15GlcA accounted for about 75% of total DON-GlcA (Warth et al. 390 
2012). Heyndrickx et al., also confirmed that DON-GlcA at the 15-position is preferential 391 
than glucuronidation of DON at the 3-position (Heyndrickx et al. 2015). In our work, we 392 
were not able to differentiate between DON-GlcA at different positions since an enzymatic 393 
hydrolysis with β-glucuronidase allowed the estimation of DON-GlcA indirectly, by 394 
subtracting free DON from total DON concentrations. 395 
In contrast to free DON and DON-GlcA, DOM-1 was not detected in any sample of 396 
our elderly or adult population. These results are consistent with previous findings in elderly 397 
from Italy (Brera et al. 2015), but also other studies in adults (Turner et al. 2011; Rodriguez-398 
Carrasco et al. 2014) and support the idea that conversion of DON to DOM-1 may not be a 399 
main metabolic pathway in humans. This may be due to the natural absence of microbiota 400 
with the enzymatic activity required for this conversion (Turner et al. 2010a). Alternatively, 401 
if DON was converted to DOM-1, this metabolite was not significantly excreted in urine 402 
samples in the present investigation. Our results are strengthened by the analytical approach 403 
we followed for DOM-1 determination; given that urine samples were treated with β-404 
glucuronidase, identification of both DOM-1 and DOM-1–glucuronide would be possible. 405 
DOM-1 has been detected in some other adult cohorts across Europe. In the experimental 406 
study of DON biomarkers in urine (Brera et al. 2015) performed in Italy, Norway and UK, 407 
DOM-1 (>LoQ) was detected in 12% of Norwegian samples, probably due to a lower LoQ 408 
compared to those used for the analysis of the samples in Italy and the UK. Similarly, 34% 409 
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of the samples of French farm workers (Turner et al. 2010a) and 38–60% of the total samples 410 
of German mil workers and controls ( Föllmann et al. 2016) were positive for DOM-1. These 411 
latter findings have been suggested to result from the transmission of rumen microbiota with 412 
de-epoxidase activity to humans (Turner et al. 2010a). Given that there is evidence to suggest 413 
changes in microbiota with increasing age, it will be useful to understand variations in the 414 
ability to detoxify DON by deepoxidation to DOM-1 in larger studies in elderly from 415 
different countries, and to consider differences by disease status. 416 
Urinary biomarkers concentrations can be used to estimate the dietary intake of DON 417 
at an individual level, which can be subsequently be compared with the PMTDI (1 μg/kg 418 
b.w./day). By assuming a 72% urinary excretion ratio of DON and 1.5 L daily urine output 419 
(Turner et al. 2010b), we showed that the estimated dietary intake of DON varied between 0 420 
and 2.33 μg/kg b.w./day for elderly. In total 10% of the elderly were shown to exceed the 421 
PMTDI, but, notably, the 75% of the elderly individuals were estimated to have dietary intake 422 
of DON < 0.5 μg/kg b.w./day, which is below the half of the PMTDI. The percentage of the 423 
elderly exceeding the PMTDI is higher than the <3% of adults aged 18-64 who exceeded the 424 
PMTDI in this analysis, though the numbers in the study were low. Higher percentages 425 
exceeding the PMTDI than those reported amongst elderly in the present study have also 426 
been reported in other studies in adults in the UK (n=35, estimated dietary intake of DON: 427 
0.008–1.24 μg/kg·b.w./day, 17% participants exceeded PMTDI) (Turner et al. 2010b), 428 
Belgium (n=239, 16-29% participants exceeded PMTDI) (Heyndrickx et al. 2015), Italy 429 
(n=52, 40% participants exceeded PMTDI) (Solfrizzo et al. 2014) and Austria (n=27, 33% 430 
participants exceeded PMTDI) (Warth et al. 2012). In contrast, lower percentages were 431 
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shown in Spain (n=22; <4% exceeded PMTDI) (Rodriguez-Carrasco et al. 2014). Our results 432 
and their comparisons with the findings of previous studies should be interpreted after 433 
considering the limitations of current ways to estimate dietary intake of DON and the small 434 
number of participants in most available studies. For example, the uncertainty in these 435 
estimations was depicted by Heyndrickx and colleagues who showed 16 and 29% of total 436 
sample to exceed PMTDI depending on the formula used (Heyndrickx et al. 2015). In our 437 
previous work in children and adolescents, we also showed significant discrepancies in the 438 
percentages of participants exceeding PMTDI, when different assumption of daily urine 439 
output were tested (Papageorgiou et al. 2018). Assumptions of the urinary excretion of DON, 440 
reported to range 50-72% in previous human studies (Turner et al. 2010b; Shephard et al. 441 
2013), may further influence the estimations of dietary intake of DON based on urinary 442 
biomarkers. Other reasons that may explain the variable estimations of the dietary intake of 443 
DON include differences in dietary habits of population residing in different countries or 444 
seasonal variations in dietary intake within a population, but also discrepancies in DON 445 
contamination of food sources as a result of environmental conditions, cultivation, handling 446 
and processing (Bullerman & Biachini, 2007; Oldenburg et al., 2012; Gratz et al., 2014). 447 
Taken together, the findings of the available studies and their comparison underpin the need 448 
for further research in the area and standardization of the methodology used for estimating 449 
dietary exposure to DON. Future investigations using larger sample sizes of elderly 450 
populations are also required to confirm our findings and allow comparisons in this age 451 
population group.  452 
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 To further explore the relationship between dietary exposure of DON and DON 453 
biomarkers, correlation analysis between the consumption of common foods contaminated 454 
with DON (based on food records over 24h prior to each urine sample collection) and total 455 
DON concentrations (pooled data for the 2 experimental days) in urine was performed. For 456 
our total samples of elderly and adults, this analysis revealed a significant positive association 457 
between flakes consumption and urinary mean total DON (ng/mg creat), but no significant 458 
correlations for any other food category were shown. The lack of pronounced associations 459 
may at least partially be explained by the fact that overall, DON exposure was relatively low 460 
amongst both elderly and adult participants and in this small sample. Limitations in the 461 
dietary assessment method (i.e., food records over a 24h period), challenges in estimating 462 
portion sizes or reporting bias may have also contributed to these non-significant 463 
associations. Nevertheless, given that urinary DON reflects to a large extent the DON dietary 464 
intake of the previous days (Turner et al. 2010b), food records over 24h prior to urine sample 465 
collection may more accurately reflect DON dietary exposure compared to FFQs, which 466 
typically capture dietary intake over a more prolonged period of time (e.g., last month) 467 
(Marin et al. 2013). For future studies investigating DON exposure, we recommend a longer 468 
recording period to get information on habitual dietary intake or intake of less frequently 469 
consumed foods. Inclusion of actual measurements of DON and metabolites in the recorded 470 
foods would be also useful in ascertaining associations between DON dietary exposure and 471 
DON biomarkers in biological samples. To minimize reporting bias and increase accuracy of 472 
portion sizes, research dietitians with experience in performing semi-structured interviews 473 
asked supplementary questions on the foods records and pictures with portion sizes were used 474 
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respectively. The food categories and example of food items used as the basis of the food 475 
records were comprehensive and previously used in DON research (Brera et al. 2015; Wells 476 
et al. 2017; Papageorgiou et al. 2018), however, some dietary sources contributing to the 477 
exposure of DON, which may be consumed less frequently at a local level, may have still 478 
been omitted (e.g., soups and sauces).  479 
We provided a detailed analysis of DON exposure in elderly, by determining DON 480 
and its main metabolites in urinary specimens and assessed intake of main food sources 481 
contaminated to DON. It is important to note that other factors including defence mechanisms 482 
and altered metabolism due to illness not investigated as part of this work may influence 483 
elderly’s sensitivity to the toxic effects of DON. Our elderly population were relatively 484 
healthy (as indicated by inclusion and exclusion criteria), implying no major impairments in 485 
gastrointestinal, renal, hepatic or immune functions. As such, our results may be less 486 
generalizable in elderly individuals with disease (e.g., cancer, renal and liver disease, 487 
gastrointestinal disorders, or immunosuppression). Furthermore, it remains unknown how 488 
DON exposure (e.g., low vs. high) affects elderly individuals who experience symptoms that 489 
resemble DON toxicity such as anorexia of ageing or unintended weight loss and whether 490 
DON biomarkers can capture such effects.  491 
Conclusions 492 
Despite their potential sensitivity to DON toxicity, the elderly are an understudied population 493 
in mycotoxin research. Although elderly individuals in this single-site, UK-based cohort were 494 
commonly exposed to DON, mean total DON concentrations were reported at moderate 495 
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levels and PMTDI for DON (1 μg/kg b.w./day) was exceeded by 10% of the population 496 
studied. Furthermore, our findings support no significant differences in DON and its 497 
metabolites between elderly (aged ≥65 years) and younger adults (aged 18-64 years). Future 498 
larger studies are needed to explore DON exposure in elderly from different regions of the 499 
UK, but also from different counties worldwide. Simultaneous assessment of urinary DON 500 
biomarkers, dietary patterns, gastrointestinal distress (as a result of ageing, disease or DON 501 
toxicity) and disease status would be important to understand DON exposure, susceptibility 502 
and toxicity in this population.  503 
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Table 1. Baseline characteristics of elderly (≥65 years) and adults (18-64 years) by sex 639 
 Elderly (≥65 years) Adults (18-64 years) 
 Men (n=10) Women (n=10) Men (n=16) Women(n=15) 
Height (cm) 170.1 (5.9)*,† 163.1 (6.6) 177.6 (5.3)* 165.5 (5.7) 
Weight (kg) 85.3 (13.3)* 67.1 (11.2) 91.1 (12.8)* 73.1 (12.1) 
BMI (kg/m2) 29.6 (5.6) 25.2 (3.6) 28.8 (3.2)* 26.7 (3.9) 
Physical activity  
  Sedentary (n, %) 
  Light (n, %) 
  Moderate (n, %) 
  Heavy (n, %) 
  Exceptional (n, %) 
 
1 (10) 
0 (0) 
8 (80) 
1 (10) 
0 (0) 
 
1(10) 
2 (20) 
7 (70) 
0 (0) 
0 (0) 
 
0 (0) 
6 (38) 
8 (50) 
1 (6) 
1 (6) 
 
0 (0) 
2 (13) 
12 (80) 
1 (7) 
0 (0) 
Urine creatinine (mg/dl) 110 (57)* 38 (24)‡ 124 (88) 114 (84) 
The Table includes adult data previously presented in Wells et al. 2017. *, p<0.05, significant different from women in the 640 
same age group; †, p<0.05, significant different from adult men; ‡, p<0.05, significant different from adult women.  641 
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Table 2. Unadjusted and creatinine-adjusted DON and metabolites concentrations by day 643 
and sex in elderly and adults.644 
Age 
Group 
 Total DON  Free DON DON-GlcA DOM-1 
Day 1 2 1 2 1 2 1 2 
Elderly 
Men 
(n=10) 
Incidence 90 90 70 60 90 90 nd nd 
%Total DON N/A N/A 17 9 83 91 nd nd 
Unadjusted (ng/mL) 
Mean  26.7 20.1 5.0 2.2 21.7 17.8 nd nd 
Median  7.2 13.9 0.6 1.0 5.5 12.0 nd nd 
Min-Max  0-186 0-65.1 0-42.0 0-11.8 0-144 0-53.3 nd nd 
Adjusted (ng/mg creatinine) 
Mean 22.2 28.0 3.8 3.2 18.5 21.8 nd nd 
Median 11.2 11.6 1.6 0.7 8.8 10.3 nd nd 
Min-Max 0-82.9 0-97.0 0.0-18.7 0.0-12.5 0-64.1 0-56.8 nd nd 
Elderly 
Women 
(n=10) 
Incidence 90 90 90 70 90 90 nd nd 
%Total DON N/A N/A 11 11 89 89 nd nd 
Unadjusted (ng/mL) 
Mean  8.0 8.8 0.8 1.0 7.3 7.8 nd nd 
Median  6.2 8.1 0.9 0.8 5.7 7.8 nd nd 
Min-Max  0-28.8 0-17.5 0.1-1.8 0-3.3 0-27.0 0.0-14.2 nd nd 
Adjusted (ng/mg creatinine) 
Mean 22.4 29.1 2.3 2.8 20.1 26.3 nd nd 
Median 15.7 24.3 2.0 2.5 13.8 22.7 nd nd 
Min-Max 0.0-42.5 0-81.0 1.1-5.7 0.0-7.8 0-39.9 0-76.3 nd nd 
Adults 
Men  
(n=16) 
Incidence  100 100 100 100 100 100 nd nd 
%Total DON N/A N/A 16 15 84 85 nd nd 
Unadjusted (ng/mL) 
Mean  13.1 18.1 2.1 2.9 11.0 15.2 nd nd 
Median 11.9 12.6 1.8 1.9 7.1 11.0 nd nd 
Min-Max  2.2-19.4 5.1-58.8 0.3-4.2 0.5-13.8 1.8-26.8 4.3-45.0 nd nd 
Adjusted (ng/mg creatinine) 
Mean 24.3 21.3 4.2 3.2 20.0 18.1 nd nd 
Median 10.9 14.4 1.8 2.1 9.8 12.2 nd nd 
Min-Max 0.5-153 2.5-62.3 0.1-31.5 0.4-12.7 0.4-122 2.1-55.4 nd nd 
Adult 
Women 
(n=15)  
Incidence 100 100 87 87 100 100 nd nd 
%Total DON N/A N/A 15 16 85 84 nd nd 
Unadjusted (ng/mL) 
Mean 12.4 14.1 2.0 2.4 10.4 11.8 nd nd 
Median 10.7 10.1 1.8 1.3 9.0 9.6 nd nd 
Min-Max  3.3-40.6 0.9-36.0 0.3-4.2 0.1-8.6 2.9-31.9 0.7-27.4 nd nd 
Adjusted (ng/mg creatinine) 
Mean 12.7 18.2 1.9 2.8 10.8  15.4 nd nd 
Median 11.3 11.3 1.6 2.5 10.0 10.5 nd nd 
Min-Max 3.9-27.8 1.0-66.2 0.2-4.7 0.2-9.3 3.3-23.1 0.8-56.8 nd nd 
  
The Table includes adult data previously presented in Wells et al. 2017. Data are presented as mean, medium and min 
(minimum) - max (maximum); DON: deoxynivalenol; DON: deoxynivalenol; DON-GlcA: deoxynivalenol 
glucuronide; DOM-1: deepoxy-deoxynivalenol; min: minimum; max: maximum; nd: not detected. LOQ for free DON 
was 0.25 ng/mL and for DON-GlcA and DOM-1 0.50 ng/mL. 
 
Table 3. Consumption of food categories that commonly contribute to dietary DON 
exposure in elderly (n=20) and adults (n=30).  
Food category  Elderly (n = 20) Adults (n=30) 
Bread (g/d)  101±49 (0-203) 89±60 (0-203) 
Flakes (g/d) 22±16 (0–60)* 12±14 (0-50) 
Breakfast cereals (g/d) 4±8 (0–23) 5±8 (0–30) 
Other breads (g/d) 17±30 (0–90) 34±45 (0–135) 
Biscuits (g/d)  15±15 (0-53)* 8±13 (0-60) 
Baked goods (g/d) 28±32 (0–112)* 15±32 (0–112) 
Pizza (g/d) 9±30 (0-128) 17±41 (0-128) 
Pasta (g/d) 23±47 (0–115) 60±77 (0–230) 
Wheat germ (g/d) 2±5 (0-15) 1±3 (0-15) 
Beer (g/d) 43±105 (0-431) 91±153 (0-431) 
Pancakes (g/d) 6±28 (0-124) 7±23 (0-93) 
Total (g/d) 269±148 (65–625) 339±180 (45-658) 
Data are presented as mean±1SD (range: minimum-maximum). Analysis was performed in 20 elderly and 30 adults 
with complete data. *, p<0.05, significant different from adults. 
 
